Chemotherapy targeting cancer stem cells.

Haiguang Liu, Lin Lv, Kai YangPubMed 2015

TL;DR

Conventional chemotherapy often fails due to cancer stem cells (CSCs), which are resistant to treatment and drive relapse. This review explores strategies for targeting CSCs, including methods for enriching them, discovering new drugs, and developing advanced drug delivery systems. The complexity of CSC hierarchy suggests that combination therapies targeting both CSCs and differentiated cancer cells are crucial for effective cancer treatment.

What Problem Does This Paper Address?

The paper addresses the persistent challenge of chemotherapy resistance and cancer relapse, which is largely attributed to a small subpopulation of cells known as cancer stem cells (CSCs). While conventional chemotherapy effectively kills the majority of rapidly dividing cancer cells, it often spares CSCs. These CSCs possess self-renewal and differentiation capabilities, allowing them to repopulate the tumor, leading to treatment failure, relapse, and metastasis. The authors aim to provide a comprehensive overview of current research and future strategies for developing more effective chemotherapy that specifically targets these resilient CSCs.

Methods

This review synthesizes existing research and proposes future directions, rather than introducing novel experimental methods. The key "methods" discussed are categorized as follows:

  • Cancer Stem Cell Enrichment:
    • Phenotypic Isolation: Identifying CSCs based on specific cell surface markers (e.g., CD133, CD44, ALDH1) or intrinsic properties like autofluorescence.
  • Enrichment via Chemotherapy/Radiotherapy: Observing that CSCs can be enriched after conventional treatments due to their inherent resistance.
  • Inducing Epithelial-to-Mesenchymal Transition (EMT): Manipulating cellular pathways to induce a stem-like phenotype.
  • Serum-Free Cultivation: Using specific growth factors to maintain CSC characteristics in vitro.
  • Drug Discovery:
    • High-Throughput Screening (HTS): Screening large compound libraries to identify novel drugs that selectively kill CSCs.
  • Validation of Old Drugs: Repurposing existing drugs (e.g., metformin, disulfiram, thioridazine) that have shown efficacy against CSCs.
  • Drug Delivery Systems:
    • Passive Targeting: Utilizing the Enhanced Permeability and Retention (EPR) effect of tumors, pH-sensitivity, and thermosensitivity.
  • Active Targeting: Employing monoclonal antibodies specific to CSC markers.
  • Multifunctional Nanocarriers: Designing sophisticated delivery systems that combine passive and active targeting, along with drug encapsulation, to improve efficacy and reduce side effects.

Datasets

Not discussed in the paper. The paper is a review article and does not present original experimental data or datasets.

Key Insights and Ideas

  • CSCs as the Root of Relapse: The paper strongly emphasizes that CSCs, not just the bulk of cancer cells, are the primary drivers of chemotherapy resistance, relapse, and metastasis.
  • Limitations of Conventional Chemotherapy: Standard chemotherapy targets rapidly dividing cells, leaving dormant or resistant CSCs untouched, which ultimately leads to treatment failure.
  • The Promise of Targeted Therapies: While targeting CSCs might not immediately shrink tumors, it holds the potential for long-term tumor eradication by eliminating the source of recurrence.
  • Complexity of CSC Hierarchy: The concept of a strict hierarchy is being challenged, with evidence suggesting that differentiated cells can dedifferentiate into CSCs, indicating a more dynamic and complex cellular landscape.
  • Multifaceted Approach Needed: Effective cancer treatment will likely require a combination of strategies, including targeting CSCs, differentiated cells, and utilizing advanced drug delivery systems.
  • Repurposing Existing Drugs: Existing drugs like metformin and disulfiram show promise in targeting CSCs, offering a faster route to clinical application compared to developing entirely new compounds.
  • Nanomedicine's Role: Multifunctional nanocarriers are highlighted as a key technology for delivering targeted therapies efficiently and with fewer side effects.

Key Results

As a review article, this paper does not present quantitative experimental results. Instead, it synthesizes findings from numerous studies. Key qualitative findings include:

  • Salinomycin: Identified through HTS as a compound that inhibits breast CSCs 100-fold more effectively than paclitaxel, though concerns about its toxicity in normal cells exist.
  • Metformin: Shown to inhibit CSC sphere formation, sensitize various cancers to therapy, and reduce cancer risk in diabetic patients.
  • Disulfiram: Demonstrated cytotoxic effects on CSC-like cells across multiple cancer types, inducing apoptosis and reversing drug resistance.
  • Thioridazine: Selectively targets leukemia stem cells without harming normal stem cells and shows anti-cancer potential in other cancers.
  • Herceptin-conjugated nanocarriers: Significantly improved cellular uptake and cytotoxicity in HER2-overexpressing breast cancer models.
  • Multifunctional nanocarriers: Show enhanced anti-cancer efficacy compared to simpler delivery systems by combining multiple targeting and delivery mechanisms.

Limitations and Future Work

Limitations:

  • Enrichment Purity: Methods for enriching CSCs often result in populations that are not purely CSCs, necessitating the use of multiple enrichment strategies.
  • Drug Toxicity: Some promising CSC-targeting drugs, like salinomycin, exhibit significant toxicity in normal cells, limiting their clinical applicability.
  • Complexity of Hierarchy: The dynamic interconversion between CSCs and differentiated cells suggests that targeting only CSCs might be insufficient.
  • Need for Clinical Validation: Many promising findings are based on in vitro or preclinical studies, and extensive clinical validation is required before widespread use.

Future Work:

  • Developing Novel Drugs: Continued search for new, selective, and less toxic drugs targeting CSCs.
  • Optimizing Drug Delivery: Designing more sophisticated and multifunctional nanocarriers for precise drug delivery to CSCs.
  • Combination Therapies: Investigating and validating combination therapies that simultaneously target both CSCs and the bulk of differentiated cancer cells.
  • Understanding CSC Hierarchy: Further research into the complex interactions and interconversions within the CSC hierarchy to inform therapeutic strategies.
  • Identifying New Biomarkers: Discovering and validating new CSC-specific biomarkers for improved isolation and targeted therapy.

Summary updated

Abstract

Conventional chemotherapy is the main treatment for cancer and benefits patients in the form of decreased relapse and metastasis and longer overall survival. However, as the target therapy drugs and delivery systems are not wholly precise, it also results in quite a few side effects, and is less efficient in many cancers due to the spared cancer stem cells, which are considered the reason for chemotherapy resistance, relapse, and metastasis. Conventional chemotherapy limitations and the cancer stem cell hypothesis inspired our search for a novel chemotherapy targeting cancer stem cells. In this review, we summarize cancer stem cell enrichment methods, the search for new efficient drugs, and the delivery of drugs targeting cancer stem cells. We also discuss cancer stem cell hierarchy complexity and the corresponding combination therapy for both cancer stem and non-stem cells. Learning from cancer stem cells may reveal novel strategies for chemotherapy in the future.
BibTeX
@inproceedings{liu2015chemotherapy,
  author = {Haiguang Liu and Lin Lv and Kai Yang},
  title = {{Chemotherapy targeting cancer stem cells.}},
  booktitle = {PubMed},
  year = {2015},
}
Figure